Ann Arbor, MI-based Accuri Cytometers has $5 million to fund ongoing testing and the upcoming commercial launch of its Accuri C6 Flow Cytometer System. Designed for routine use by biomedical researchers in their own labs, Accuri’s flow cytometer system is a benchtop cell analysis system that the company says is more user friendly and cost effective than industry-leading flow cytometers. The money came in the form of a Series B financing led by Baird Venture Partners and co-led by Arboretum Ventures. Pete Shagory of Baird and Tim Petersen of Arboretum will join Accuri’s board of directors.